NEWTON,
Mass., Feb. 3, 2025 /PRNewswire/
-- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a
commercial-stage pharmaceutical company pioneering novel cancer
therapies, today announced that the Company granted an aggregate of
28,000 restricted stock units (RSUs) to three newly-hired
employees. These RSU awards were granted as of January 31, 2025 (the "Grant Date") pursuant to
the Company's 2022 Inducement Stock Incentive Plan, as amended, as
inducements material to the new employees entering into employment
with Karyopharm in accordance with Nasdaq Listing Rule
5635(c)(4).
Each RSU award will vest over three years, with 33 1/3% of the
shares underlying the RSU award vesting on each of the three
consecutive anniversaries of the Grant Date. The vesting of each
RSU award is subject to the employee's continued service as an
employee of, or other service provider to, Karyopharm through the
applicable vesting dates.
In addition, each RSU award will be immediately exercisable in
full if, on or prior to the first anniversary of the consummation
of a "change in control event," the employee's employment is
terminated for "good reason" by the employee or terminated without
"cause" by Karyopharm (as such terms are defined in the 2022
Inducement Stock Incentive Plan, as amended).
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a
commercial-stage pharmaceutical company whose dedication to
pioneering novel cancer therapies is fueled by a belief in the
extraordinary strength and courage of patients with cancer. Since
its founding, Karyopharm has been an industry leader in oral
compounds that address nuclear export dysregulation, a
fundamental mechanism of oncogenesis. Karyopharm's lead
compound and firstinclass, oral exportin 1 (XPO1) inhibitor,
XPOVIO® (selinexor), is approved in the U.S.
and marketed by the Company in three oncology indications. It
has also received regulatory approvals in various indications in a
growing number of exU.S. territories and countries, including
Europe and the United Kingdom (as NEXPOVIO®) and
China. Karyopharm has
a focused pipeline targeting indications in multiple high
unmet need cancers, including in multiple myeloma, endometrial
cancer, myelofibrosis, and diffuse large
B-cell lymphoma (DLBCL). For more information about our
people, science and pipeline, please visit www.karyopharm.com, and
follow us on LinkedIn and on X at @Karyopharm.
XPOVIO® and NEXPOVIO® are registered
trademarks of Karyopharm Therapeutics Inc.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-302363681.html
SOURCE Karyopharm Therapeutics Inc.
